Vitiligo

Vitiligo is described as multifactorial in origin. The grounding supports a combination of genetic susceptibility, oxidative stress, and autoimmune melanocyte destruction rather than a single cause.

The central biological event is loss of melanocytes, leading to depigmented skin and mucosa. Oxidative stress with elevated reactive oxygen species can damage melanocyte molecules and organelles, expose melanocyte antigens, and contribute to cell death, including apoptosis and other death pathways. Immune dysregulation then drives much of the melanocyte destruction, with heightened innate immunity, type 1-skewed T helper responses, incompetent regulatory T cells, and CD8+ cytotoxic T lymphocyte activity.

Genetic susceptibility loci identified in genome-wide association studies are supported as risk factors. The literature also links oxidative stress and immune dysregulation to disease development, but the grounding does not support additional specific clinical risk factors.

Treatment is described at the modality level as drug therapy and surgery. The grounding supports use of pharmacologic approaches including JAK-STAT pathway inhibitors for inflammatory or autoimmune vitiligo, and surgical approaches for stable, difficult-to-treat lesions when non-invasive procedures are ineffective. Surgical management is framed as cell and tissue transplantation techniques.